HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Psoriasis

 

Deucravacitinib Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

September 10, 2022

Bristol Myers Squibb announced the US FDA has approved their first-in-class, oral, selective, allosteric TYK2 inhibitor, deucravacitinib (Sotkytu), for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Deucravacitinib Effectively Treats Moderate-to-Severe Plaque Psoriasis

January 20, 2022

Deucravacitinib selectively binds to a unique pocket in the regulatory domain of TYK2 instead of the highly conserved active site of the catalytic domain,” investigators explained. “This leads to targeted inhibition of immune pathways that are central to psoriasis while limiting off-target effects.”